Sepracor, Inc. (SEPR) Announces Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024
10/26/2009 1:11:56 PM
More...
|
Sepracor, Inc. (SEPR) Deal Closes, CEO in Line for $11 Million
10/21/2009 9:51:14 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd. and Sepracor, Inc. (SEPR) Announce Completion of Subsequent Offering Period and Exercise of Top-Up Option
10/20/2009 9:29:29 AM
More...
|
Sepracor, Inc. (SEPR) Agent Reduces Seizures as Add-on Epilepsy Therapy
10/14/2009 11:04:45 AM
More...
|
Sepracor, Inc. (SEPR) Announces Expiration of Hart-Scott-Rodino Waiting Period
9/24/2009 9:41:13 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd. (JOBS) to Buy U.S. Drug Firm Sepracor, Inc. (SEPR) for $2.6 Billion
9/3/2009 6:56:54 AM
More...
|
Sepracor, Inc. (SEPR) Announces New Drug Submission (NDS) to Health Canada for STEDESA(TM) as Adjunctive Treatment for Epilepsy
8/10/2009 9:53:51 AM
More...
|
Sepracor, Inc. (SEPR) Reports Strong Second Quarter 2009 Operating Results and Increases Financial Guidance for 2009
7/24/2009 8:39:57 AM
More...
|
Sepracor, Inc. (SEPR) Sets Conference Call and Webcast for Second Quarter 2009 Operating Results
7/20/2009 10:03:59 AM
More...
|
Sepracor, Inc. (SEPR) Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics
7/6/2009 9:56:27 AM
More...
|
|